```
=> b reg
FILE 'REGISTRY' ENTERED AT 17:17:44 ON 02 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   30 NOV 2008  HIGHEST RN 1077629-73-2
DICTIONARY FILE UPDATES:  30 NOV 2008  HIGHEST RN 1077629-73-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l8
L4              STR
```




```
VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  18

STEREO ATTRIBUTES: NONE
L8          358 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED    5426 ITERATIONS                          358 ANSWERS
SEARCH TIME: 00.00.01



=> d que sta l10
L4              STR
```



VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE
L5 STR



VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 22

STEREO ATTRIBUTES: NONE
L6 STR



```
VAR G1=O/S
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  22

STEREO ATTRIBUTES: NONE
L8          358 SEA FILE=REGISTRY SSS FUL L4
L10          45 SEA FILE=REGISTRY SUB=L8 SSS FUL (L5 OR L6)

100.0% PROCESSED      45 ITERATIONS                             45 ANSWERS
SEARCH TIME: 00.00.01



=> b hcap
FILE 'HCAPLUS' ENTERED AT 17:17:57 ON 02 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Dec 2008  VOL 149 ISS 23
FILE LAST UPDATED: 1 Dec 2008  (20081201/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitrn fhitstr l15 tot
```

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:959196 HCAPLUS
DN 147:322957
TI Preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Ozimec, Ivana; Trojko, Rudolf
PA Glaxosmith Kline Istrazivocki Centar Zagreb, D.O.O., Croatia
SO U.S., 18pp., Cont.-in-part of Appl. No. PCT/HR03/00014.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US-----7262309	B2	20070828	2004US-000963979	20041012
US-20050130964	A1	20050616		
HR-----2002000303	B1	20070531	2002HR-000000303	20020410
WO--2003084961	A1	20031016	2003WO-HR0000014	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2002HR-000000303	A	20020410		
2003WO-HR0000014	A2	20030409		

OS MARPAT 147:322957
GI



I

Q=  Q1=  Q2= 

AB The present invention relates to benzonaphthoazulene derivs. of thiophene class [I; X = CH2, O, S, S(:O), S(:O)2, or (un)protected NH; Y, Z = H, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, CF3, halo-C1-4 alkyl, HO, C1-4 alkoxy, CF3O, C1-4 alkanoyl, NH2, amino-C1-4 alkyl, C1-4 alkylamino, N-(C1-4 alkyl)amino, N,N-di(C1-4 alkyl)amino, SH, C1-4 alkylthio, C1-4 alkylsulfonyl, C1-4 alkylsulfinyl, CO2H, C1-4 alkoxycarbonyl, NO2; one of the ring A and B is present while is the other one is absent, and is selected from the group consisting of Q, Q1, and Q2; R1 = (un)substituted C1-7 alkyl, C1-7 alkyloxycarbonyl, (CH2)n-Q3-(CH2)n-Q4-NR2R3; wherein R2, R3 = H, C1-4 alkyl, or aryl or NR2R3 taken together forms (un)substituted heterocyclyl or heteroaryl; n = an integer of 0-3; m = an integer of 1-3; Q3, Q4 = O, S, C(yl)(y2), N(yl), C(yl):CH, C.tplbond.C; y1, y2 = H, halogen, HO, C1-4 alkoxy, C1-4 alkanoyl, SH, C1-4 alkylthio, C1-4 alkylsulfonyl, C1-4 alkylsulfinyl, NO2, etc.; or y1 and y2 taken together with the carbon atom to which they are attached form carbonyl or imino

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
4-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]morpholine 613671-44-6P,
1-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]piperidine 613671-45-7P,
1-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]pyrrolidine 613671-46-8P,
Dimethyl[1-methyl-2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor prodn. for treating inflammation and rheumatoid arthritis)
IT 613671-14-0P, 8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production for treating inflammation and rheumatoid arthritis)
RN 613671-14-0 HCAPLUS
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
group] and their pharmacol. acceptable salts and solvates. These compds. inhibit the prodn. of tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), possess antiinflammatory or analgetic effects, and are useful for treating inflammation assocd. with TNF-α, in particular rheumatoid arthritis. Thus, Et 2-mercaptoacetate (0.005 mol) and triethylamine (1.0 mL) were added to a soln. of 12-chloro-5-oxabenzo[4,5]cyclohepta[1,2-b]naphthalene-13-carboxaldehyde (0.005 mol) in 10 mL pyridine and the mixt. was refluxed under stirring for 3 h to give 8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid Et ester as a white solid. Two compds., namely dimethyl[2-(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-ylmethoxy)ethyl]amine and dimethyl[3-(11-methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-ylmethoxy)propyl]amine, showed activity in at least two investigated assays selected from (1) inhibitory action on TNF-α and IL-1 secretion in human peripheral blood mononuclear cells or mouse peritoneal macrophages, resp., in vitro, (2) inhibitory action on LPS-induced excessive TNF-α or IL-1 secretion in mice, (3) writhing assay for analgetic activity in mice, and (4) LPS-induced shock in mice.
IT 613671-14-0P, 8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-15-1P, 1,8-Dithiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-16-2P, 1,8-Dithiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-17-3P, 8-Oxa-1-thiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-18-4P, 11-Methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-19-5P, 9,10,11,12-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-20-8P, 10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-21-9P, (8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-22-0P, (1,8-Dithiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-23-1P, (1,8-Dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-24-2P, (8-Oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-25-3P, (11-Methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-26-4P, (9,10,11,12-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-27-5P, (10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-28-6P, Dimethyl[2-[(8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-29-7P, Dimethyl[3-[(8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-30-0P, [3-[(8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-31-1P, Dimethyl[3-[(1,8-dithiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-32-2P, Dimethyl[2-[(1,8-dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-33-3P, Dimethyl[3-[(1,8-dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-34-4P, Dimethyl[2-[(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-35-5P, Dimethyl[3-[(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-36-6P, Dimethyl[3-[(11-methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-37-7P, Dimethyl[2-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-38-8P, Dimethyl[3-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-39-9P, (3-[(9,10,11,12-Tetrahydro-10-oxa-3-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-40-2P, (Methyl)[3-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-41-3P, Dimethyl[2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-42-4P, Dimethyl[3-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-43-5P,

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:729528 HCAPLUS
DN 143:179664
TI Benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
IN Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Ozimeclandek, Ivana; Trojko, Rudolf; Rupcic, Renata
PA Pliva-Istrazivacki Institut D.O.O., Croatia
SO PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2005072728	A1	20050811	2005WO-HR0000008	20050127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA-----2554886	A1	20050811	2005CA-002554886	20050127
EP-----1708696	A1	20061011	2005EP-000702165	20050127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN-----1938016	A	20070328	2005CN-080010392	20050127
JP--2007519698	T	20070719	2006JP-000550310	20050127
IN---200604130	A	20070817	2006IN-000004130	20060718
US-20070173499	A1	20070726	2006US-000587823	20061220
PRAI 2004HR-000000104	A	20040130		
2005WO-HR0000008	W	20050127		

OS MARPAT 143:179664
AB The present invention relates to the use of compds. from the group of benzonaphthoazenes and of their pharmaceutically acceptable salts and solvates for the manufacture of a pharmaceutical formulation for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochem. equilibrium of biogenic amines or other transmitters. Thus, in vitro affinity of benzonaphthoazulenes for binding to recombinant human 5-HT2A and 5-HT2C serotonin receptors expressed in CHO-K1 or COS-7 cells was determined using a radioligand. The radioligand binding was inhibited by the test compds. proportionally to the affinity of a certain compound for the receptor and to the concentration of the compound Compds. showing IC50 and Ki in concns. lower than 1 μM were considered to be active. Compound dimethyl-[3-(1,8-dithia-benzo[e]naphtho[3,2-h]azulen-2-ylmethoxy)-propyl]-amine and dimethyl-[3-(3, 10-dithia-benzo[e]naphtho[1,2-h]azulen-2-ylmethoxy)-propyl]-amine showed binding affinity to 5-HT2A and 5-HT2C serotonin receptors expressed as IC50 value less than 200 nM and Ki value less than 100 nM.
IT 613671-14-0 613671-15-1 613671-16-2
613671-17-3 613671-18-4 613671-19-5
613671-20-8 613671-21-9 613671-22-0
613671-23-1 613671-24-2 613671-25-3
613671-26-4 613671-27-5 613671-28-6
613671-29-7 613671-30-0 613671-31-1
613671-32-2 613671-33-3 613671-34-4
613671-35-5 613671-36-6 613671-37-7
613671-38-8 613671-39-9 613671-40-2
613671-41-3 613671-42-4 613671-43-5
613671-44-6 613671-45-7 613671-46-8
861398-65-4 861398-66-5 861398-67-6
861398-68-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzonaphthoazulenes for manufacture of pharmaceutical formulations for treatment and prevention of central nervous system diseases and disorders)

L15 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
IT 613671-14-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(benzonaphthoazulenes for manufacture of pharmaceutical formulations for treatment and prevention of central nervous system diseases and disorders)
RN 613671-14-0 HCAPLUS
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:818427 HCAPLUS
DN 139:323507
TI Preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production
IN Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Ozimec, Ivana; Trojko, Rudolf
PA Pliva D.D., Croatia
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO--2003084961	A1	20031016	2003WO-HR0000014	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HR--2002000303	B1	20070531	2002HR-000000303	20020410
CA-----2481850	A1	20031016	2003CA-002481850	20030409
AU--2003259958	A1	20031020	2003AU-000259958	20030409
EP-----1492795	A1	20050105	2003EP-000745847	20030409
EP-----1492795	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR--2003009097	A	20050209	2003BR-000009097	20030409
CN-----1649876	A	20050803	2003CN-000809957	20030409
JP--2005526827	T	20050908	2003JP-000582158	20030409
AT------310005	T	20051215	2003AT-000745847	20030409
NZ------535622	A	20060331	2003NZ-000535622	20030409
ES-----2253694	T3	20060601	2003ES-000745847	20030409
RU-----2318827	C2	20080310	2004RU-000132866	20030409
ZA--2004008059	A	20051006	2004ZA-000008059	20041006
MX-2004PA09872	A	20050816	2004MX-PA0009872	20041008
US-----7262309	B2	20070828	2004US-000963979	20041012
US-20050130964	A1	20050616		
NO--2004004508	A	20041109	2004NO-000004508	20041021
IN---200402522	A	20070921	2004IN-000002522	20041109
US-20050137249	A1	20050623	2005US-000510867	20050223
PRAI 2002HR-000000303	A	20020410		
2003WO-HR0000014	W	20030409		

OS MARPAT 139:323507
GI



I

AB Thienonaphthazulenes I [X = CH2, O, S, S(O), SO2, NH, protected NH; Y, Z = halogen, alkyl, alkenyl, alkynyl, CF3, haloalkyl, OH, alkoxy, F3CO, acyl, (un)substituted amino, aminoalkyl, SH, alkylthio, alkylsulfinyl, alkylsulfonyl, CO2H, alkoxycarbonyl, NO2; R1 = halogen, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, OH, SH, CO2H, acyl, CONH2, alkylsulfonyl, alkylsulfinyl, NO2; R2R3, R3R4 = (un)substituted CH:CHCH:CH, (CH2)4] were prepd. for use as antiinflammatory agents, esp. as inhibitors of TNF-α prodn. and interleukin-1 prodn., as well as analgesics (no data). Thus, I [X = O, Y, Z, R4 = H, R1 = CH2OCH2CH2NMe2, R2R3 = CH:CHCH:CH] was prepd. from 2-(2-naphthyloxy)phenylacetic acid, HSCH2CO2Et, and Me2NCH2CH2Cl.HCl.

IT 613671-14-0P 613671-15-1P 613671-16-2P
613671-17-3P 613671-18-4P 613671-19-5P
613671-20-8P 613671-21-9P 613671-22-0P
613671-23-1P 613671-24-2P 613671-25-3P
613671-26-4P 613671-27-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)

IT 613671-38-8P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
USES (Uses)
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)

IT 613671-28-6P 613671-29-7P 613671-30-0P
613671-31-1P 613671-32-2P 613671-33-3P
613671-34-4P 613671-35-5P 613671-36-6P
613671-37-7P 613671-39-9P 613671-40-2P
613671-41-3P 613671-42-4P 613671-43-5P
613671-44-6P 613671-45-7P 613671-46-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)

IT 613671-14-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)

RN 613671-14-0 HCAPLUS
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:18:23 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:18:23 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:18:23 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitrn fhitstr l17 tot
```

L17 ANSWER 1 OF 4 USPATFULL on STN

AN 2007:198151 USPATFULL
TI Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec Landek, Ivana, Zagreb, CROATIA
Trojko, Rudolf, Bjelovar, CROATIA
Rupcic, Renata, Zagreb, CROATIA
PI US-20070173499 A1 20070726
AI 2005US-000587823 A1 20050127 (10)
2005WO-HR0000008 20050127
20061220 PCT 371 date
PRAI 2004HR-020040104 20040130
DT Utility
FS APPLICATION
LREP GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1058
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to the use of compounds from the group of benzonaphthoazulenes and of their pharmaceutically acceptable salts and solvates for the treatment and prevention of diseases, damages and disorders of the central nervous system (CNS) caused by disorders of the neurochemical equilibrium of biogenic amines or other transmitters, and to methods of manufacture of such compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-14-0 613671-15-1 613671-16-2
613671-17-3 613671-18-4 613671-19-5
613671-20-8 613671-21-9 613671-22-0
613671-23-1 613671-24-2 613671-25-3
613671-26-4 613671-27-5 613671-29-7
613671-30-0 613671-31-1
613671-32-2 613671-33-3 613671-34-4
613671-35-5 613671-36-6 613671-37-7
613671-38-8 613671-39-9 613671-40-2
613671-41-3 613671-42-4 613671-43-5
613671-44-6 613671-45-7 613671-46-8
861398-65-4 861398-66-5 861398-67-6
861398-68-7
(benzonaphthoazulenes for manufacture of pharmaceutical formulations for treatment and prevention of central nervous system diseases and disorders)
IT 613671-14-0
(benzonaphthoazulenes for manufacture of pharmaceutical formulations for treatment and prevention of central nervous system diseases and disorders)
RN 613671-14-0 USPATFULL
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



L17 ANSWER 1 OF 4 USPATFULL on STN (Continued)

L17 ANSWER 2 OF 4 USPATFULL on STN

AN 2005:159039 USPATFULL
TI 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA PLIVA-ISTRAZIVACKI INSTITUT D.D.D., ZAGREB, CROATIA (non-U.S. corporation)
PI US-20050137249 A1 20050623
AI 2003US-000510867 A1 20030409 (10)
2003WO-HR0000014 20030409
PRAI 2002HR-000020303 20020410
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 1- or 3-thiabenzonaphthoazulene derivafives to heir pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-alpha (TNF-alpha) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-14-0P 613671-15-1P 613671-16-2P
613671-17-3P 613671-18-4P 613671-19-5P
613671-20-8P 613671-21-9P 613671-22-0P
613671-23-1P 613671-24-2P 613671-25-3P
613671-26-4P 613671-27-5P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-38-8P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-28-6P 613671-29-7P 613671-30-0P
613671-31-1P 613671-32-2P 613671-33-3P
613671-34-4P 613671-35-5P 613671-36-6P
613671-37-7P 613671-39-9P 613671-40-2P
613671-41-3P 613671-42-4P 613671-43-5P
613671-44-6P 613671-45-7P 613671-46-8P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-14-0P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
RN 613671-14-0 USPATFULL
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



L17 ANSWER 3 OF 4 USPATFULL on STN

AN 2005:152050 USPATFULL
TI 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA Pliva-Istrazivacki Institut d.o.o., Zagreb, CROATIA (non-U.S. corporation)
PI US-20050130964 A1 20050616
US-----7262309 B2 20070828
AI 2004US-000963979 A1 20041012 (10)
RLI Continuation-in-part of Ser. No. 2003WO-HR0000014, filed on 9 Apr 2003, UNKNOWN
PRAI 2002HR-020020303 20020410
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to benzonaphthoazulene derivatives of tiophene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-14-0P, 8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-15-1P, 1,8-Dithiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-16-2P, 1,8-Dithiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-17-3P, 8-Oxa-1-thiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-18-4P, 11-Methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-19-5P, 9,10,11,12-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulene-2-carboxylic acid ethyl ester 613671-20-8P, 10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester 613671-21-9P, (8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-22-0P, (1,8-Dithiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-23-1P, (1,8-Dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-24-2P, (8-Oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-25-3P, (11-Methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-26-4P, (9,10,11,12-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methanol 613671-27-5P, (10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methanol 613671-28-6P, Dimethyl[2-[(8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-29-7P, Dimethyl[3-[(8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-30-0P, [3-[(8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-31-1P, Dimethyl[3-[(1,8-dithiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-32-2P, Dimethyl[2-[(1,8-dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-33-3P, Dimethyl[3-[(1,8-dithiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-34-4P, Dimethyl[2-[(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-35-5P, Dimethyl[3-[(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-36-6P, Dimethyl[3-[(11-methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-37-7P, Dimethyl[2-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-

L17 ANSWER 3 OF 4 USPATFULL on STN (Continued)
h]azulen-2-yl)methoxy]ethyl]amine 613671-38-8P,
Dimethyl[3-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-39-9P,
[3-[(9,10,11,12-Tetrahydro-10-oxa-3-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-40-2P,
(Methyl)[3-[(9,10,11,12-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-yl)methoxy]propyl]amine 613671-41-3P,
Dimethyl[2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine 613671-42-4P,
Dimethyl[3-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine 613671-43-5P,
4-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]morpholine 613671-44-6P,
1-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]piperidine 613671-45-7P,
1-[2-[(10,11,12,13-Tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]pyrrolidine 613671-46-8P,
Dimethyl[1-methyl-2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]ethyl]amine
(prepn. of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor prodn. for treating inflammation and rheumatoid arthritis)
IT 613671-14-0P, 8-Oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid ethyl ester
(preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production for treating inflammation and rheumatoid arthritis)
RN 613671-14-0 USPATFULL
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)



L17 ANSWER 4 OF 4 USPAT2 on STN
AN 2005:152050 USPAT2
TI 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA GlaxoSmith Kline Istrazivocki Centar Zagreb, D.O.O., CROATIA (non-U.S. corporation)
PI US-----7262309 B2 20070828
AI 2004US-000963979 20041012 (10)
RLI Continuation-in-part of Ser. No. 2003WO-HR0000014, filed on 9 Apr 2003, PENDING
PRAI 2002HR-020020303 20020410
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stockton, Laura L.
LREP Young, J. Scott
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to benzonaphthoazulene derivatives of tiophene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumor necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-14-0P 613671-15-1P 613671-16-2P
613671-17-3P 613671-18-4P 613671-19-5P
613671-20-8P 613671-21-9P 613671-22-0P
613671-23-1P 613671-24-2P 613671-25-3P
613671-26-4P 613671-27-5P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-38-8P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-28-6P 613671-29-7P 613671-30-0P
613671-31-1P 613671-32-2P 613671-33-3P
613671-34-4P 613671-35-5P 613671-36-6P
613671-37-7P 613671-39-9P 613671-40-2P
613671-41-3P 613671-42-4P 613671-43-5P
613671-44-6P 613671-45-7P 613671-46-8P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
IT 613671-14-0P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
RN 613671-14-0 USPAT2
CN Benzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-carboxylic acid, ethyl ester (CA INDEX NAME)

L17 ANSWER 4 OF 4 USPAT2 on STN (Continued)



```
=> b hcap

FILE 'HCAPLUS' ENTERED AT 17:18:46 ON 02 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 2 Dec 2008  VOL 149 ISS 23
FILE LAST UPDATED: 1 Dec 2008  (20081201/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr l16 tot
```

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:959196 HCAPLUS
DN 147:322957
TI Preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Ozimec, Ivana; Trojko, Rudolf
PA Glaxosmith Kline Istrazivocki Centar Zagreb, D.O.O., Croatia
SO U.S., 18pp., Cont.-in-part of Appl. No. PCT/HR03/00014.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-----7262309	B2	20070828	2004US-000963979	20041012
US-20050130964	A1	20050616		
HR--2002000303	B1	20070531	2002HR-000000303	20020410
WO--2003084961	A1	20031016	2003WO-HR0000014	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI 2002HR-000000303	A	20020410		
2003WO-HR0000014	A2	20030409		

OS MARPAT 147:322957
GI



I

Q= 
Q1= 
Q2= 

AB The present invention relates to benzonaphthoazulene derivs. of thiophene class [I; X = CH2, O, S, S(:O), S(:O)2, or (un)protected NH; Y, Z = H, halogen, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, CF3, halo-C1-4 alkyl, HO, C1-4 alkoxy, CF3O, C1-4 alkanoyl, NH2, amino-C1-4 alkyl, C1-4 alkylamino, N-(C1-4 alkyl)amino, N,N-di(C1-4 alkyl)amino, SH, C1-4 alkylthio, C1-4 alkylsulfonyl, C1-4 alkylsulfinyl, CO2H, C1-4 alkoxycarbonyl, NO2; one of the ring A and B is present while is the other one is absent, and is selected from the group consisting of Q, Q1, and Q2; R1 = (un)substituted C1-7 alkyl, C1-7 alkyloxycarbonyl, (CH2)n-Q3-(CH2)n-Q4-NR2R3; wherein R2, R3 = H, C1-4 alkyl, or aryl or NR2R3 taken together forms (un)substituted heterocyclyl or heteroaryl; n = an integer of 0-3; m = an integer of 1-3; Q3, Q4 = O, S, C(y1)(y2), N(y1), C(y1):CH, C.tplbond.C; y1, y2 = H, halogen, HO, C1-4 alkoxy, C1-4 alkanoyl, SH, C1-4 alkylthio, C1-4 alkylsulfonyl, C1-4 alkylsulfinyl, NO2, etc.; or y1 and y2 taken together with the carbon atom to which they are attached form carbonyl or imino

L16 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
group] and their pharmacol. acceptable salts and solvates. These compds. inhibit the prodn. of tumor necrosis factor-α (TNF-α) and interleukin-1 (IL-1), possess antiinflammatory or analgetic effects, and are useful for treating inflammation assocd. with TNF-α, in particular rheumatoid arthritis. Thus, Et 2-mercaptoacetate (0.005 mol) and triethylamine (1.0 mL) were added to a soln. of 12-chloro-5-oxabenzo[4,5]cyclohepta[1,2-b]naphthalene-13-carboxaldehyde (0.005 mol) in 10 mL pyridine and the mixt. was refluxed under stirring for 3 h to give 8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulene-2-carboxylic acid Et ester as a white solid. Two compds., namely dimethyl[2-(8-oxa-1-thiabenzo[e]naphtho[1,2-h]azulen-2-ylmethoxy)ethyl]amine and dimethyl[3-(11-methoxy-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-ylmethoxy)propyl]amine, showed activity in at least two investigated assays selected from (1) inhibitory action on TNF-α and IL-1 secretion in human peripheral blood mononuclear cells or mouse peritoneal macrophages, resp., in vitro, (2) inhibitory action on LPS-induced excessive TNF-α or IL-1 secretion in mice, (3) writhing assay for analgetic activity in mice, and (4) LPS-induced shock in mice.
IT 613671-61-7P, Dimethyl[2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl]methoxy]propyl]amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production for treating inflammation and rheumatoid arthritis)
RN 613671-61-7 HCAPLUS
CN 1-Propanamine, N,N-dimethyl-2-[(10,11,12,13-tetrahydrobenzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-yl)methoxy]- (CA INDEX NAME)



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:818427 HCAPLUS
DN 139:323507
TI Preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production
IN Mercep, Mladen; Mesic, Milan; Pesic, Dijana; Ozimec, Ivana; Trojko, Rudolf
PA Pliva D.D., Croatia
SO PCT Int. Appl., 59 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO--2003084961	A1	20031016	2003WO-HR0000014	20030409
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
HR--2002000303	B1	20070531	2002HR-000000303	20020410
CA-----2481850	A1	20031016	2003CA-002481850	20030409
AU--2003259958	A1	20031020	2003AU-000259958	20030409
EP-----1492795	A1	20050105	2003EP-000745847	20030409
EP-----1492795	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR--2003009097	A	20050209	2003BR-000009097	20030409
CN-----1649876	A	20050803	2003CN-000809957	20030409
JP--2005526827	T	20050908	2003JP-000582158	20030409
AT-------310005	T	20051215	2003AT-000745847	20030409
NZ------535622	A	20060331	2003NZ-000535622	20030409
ES-----2253694	T3	20060601	2003ES-000745847	20030409
RU-----2318827	C2	20080310	2004RU-000132866	20030409
ZA--2004008059	A	20051006	2004ZA-000008059	20041006
MX--2004PA09872	A	20050816	2004MX-PA0009872	20041008
US-----7262309	B2	20070828	2004US-000963979	20041012
US-20050130964	A1	20050616		
NO---2004004508	A	20041109	2004NO-000004508	20041021
IN----200402522	A	20070921	2004IN-000002522	20041109
US-20050137249	A1	20050623	2005US-000510867	20050223
PRAI 2002HR-000000303	A	20020410		
2003WO-HR0000014	W	20030409		

OS MARPAT 139:323507
GI



I

AB Thienonaphthazulenes I [X = CH2, O, S, S(O), SO2, NH, protected NH; Y, Z = halogen, alkyl, alkenyl, alkynyl, CF3, haloalkyl, OH, alkoxy, F3CO, acyl, (un)substituted amino, aminoalkyl, SH, alkylthio, alkylsulfinyl, alkylsulfonyl, CO2H, alkoxycarbonyl, NO2; R1 = halogen, (un)substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, OH, SH, CO2H, acyl, CONH2, alkylsulfonyl, alkylsulfinyl, NO2; R2R3, R3R4 = (un)substituted CH:CHCH:CH, (CH2)4] were prepared for use as antiinflammatory agents, especially as inhibitors of TNF-α production and interleukin-1 production, as well as analgesics (no data). Thus, I [X = O, Y,

L16 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN (Continued)
Z, R4 = H, R1 = CH2OCH2CH2NMe2, R2R3 = CH:CHCH:CH] was prepd. from 2-(2-naphthyloxy)phenylacetic acid, HSCH2CO2Et, and Me2NCH2CH2Cl.HCl.
IT 613671-61-7P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
RN 613671-61-7 HCAPLUS
CN 1-Propanamine, N,N-dimethyl-2-[(10,11,12,13-tetrahydrobenzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-yl)methoxy]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> b uspatall
FILE 'USPATFULL' ENTERED AT 17:19:05 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:19:05 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:19:05 ON 02 DEC 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr l18 tot
```

L18 ANSWER 1 OF 3 USPATFULL on STN
AN 2005:159039 USPATFULL
TI 1-or 3-thia-benznaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA PLIVA-ISTRAZIVACKI INSTITUT D.D.D., ZAGREB, CROATIA (non-U.S. corporation)
PI US-20050137249 A1 20050623
AI 2003US-000510867 A1 20030409 (10)
2003WO-HR0000014 20030409
PRAI 2002HR-000020303 20020410
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to 1- or 3-thiabenzonaphthoazulene derivafives to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-alpha (TNF-alpha) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-61-7P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
RN 613671-61-7 USPATFULL
CN 1-Propanamine, N,N-dimethyl-2-[(10,11,12,13-tetrahydrobenzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-yl)methoxy]- (CA INDEX NAME)



L18 ANSWER 2 OF 3 USPATFULL on STN
AN 2005:152050 USPATFULL
TI 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA Pliva-Istrazivacki Institut d.o.o., Zagreb, CROATIA (non-U.S. corporation)
PI US-20050130964 A1 20050616
US-----7262309 B2 20070828
AI 2004US-000963979 A1 20041012 (10)
RLI Continuation-in-part of Ser. No. 2003WO-HR0000014, filed on 9 Apr 2003, UNKNOWN
PRAI 2002HR-020020303 20020410
DT Utility
FS APPLICATION
LREP DARBY & DARBY P.C., P. O. BOX 5257, NEW YORK, NY, 10150-5257, US
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to benzonaphthoazulene derivatives of tiophene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumour necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-61-7P, Dimethyl[2-[(10,11,12,13-tetrahydro-8-oxa-1-thiabenzo[e]naphtho[3,2-h]azulen-2-yl)methoxy]propyl]amine
(preparation of 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production for treating inflammation and rheumatoid arthritis)
RN 613671-61-7 USPATFULL
CN 1-Propanamine, N,N-dimethyl-2-[(10,11,12,13-tetrahydrobenzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-yl)methoxy]- (CA INDEX NAME)



L18 ANSWER 3 OF 3 USPAT2 on STN
AN 2005:152050 USPAT2
TI 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof
IN Mercep, Mladen, Zagreb, CROATIA
Mesic, Milan, Zagreb, CROATIA
Pesic, Dijana, Sibenik, CROATIA
Ozimec, Ivana, Trnovec, CROATIA
Trojko, Rudolf, Zagreb, CROATIA
PA GlaxoSmith Kline Istrazivocki Centar Zagreb, D.O.O., CROATIA (non-U.S. corporation)
PI US-----7262309 B2 20070828
AI 2004US-000963979 20041012 (10)
RLI Continuation-in-part of Ser. No. 2003WO-HR0000014, filed on 9 Apr 2003, PENDING
PRAI 2002HR-020020303 20020410
DT Utility
FS GRANTED
EXNAM Primary Examiner: Stockton, Laura L.
LREP Young, J. Scott
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to benzonaphthoazulene derivatives of tiophene class, to their pharmacologically acceptable salts and solvates, to processes and intermediates for the preparation thereof as well as to their antiinflammatory effects, especially to the inhibition of tumor necrosis factor-α (TNF-α) production and the inhibition of interleukin-1 (IL-1) production as well as to their analgetic action.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 613671-61-7P
(preparation of 1- or 3-thienonaphthazulenes as inhibitors of tumor necrosis factor production)
RN 613671-61-7 USPAT2
CN 1-Propanamine, N,N-dimethyl-2-[(10,11,12,13-tetrahydrobenzo[b]naphtho[2,3-f]thieno[3,2-d]oxepin-2-yl)methoxy]- (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 17:00:02 ON 02 DEC 2008)

     FILE 'HCAPLUS' ENTERED AT 17:00:10 ON 02 DEC 2008
L1            1 US20070173499/PN

     FILE 'REGISTRY' ENTERED AT 17:00:18 ON 02 DEC 2008

     FILE 'HCAPLUS' ENTERED AT 17:00:18 ON 02 DEC 2008
L2              TRA L1 1- RN :       41 TERMS

     FILE 'REGISTRY' ENTERED AT 17:00:18 ON 02 DEC 2008
L3           41 SEA L2
L4              STR
L5              STR L4
L6              STR L4
L7           16 L4
L8          358 L4 FULL
                SAV TEM J823C1M/A L8
L9            6 (L5 OR L6) SAM SUB=L8
L10          45 (L5 OR L6) FULL SUB=L8
                SAV TEM J823C1MN/A L10
L11          37 L10 AND L3
L12           8 L10 NOT L11

     FILE 'HCAOLD' ENTERED AT 17:12:30 ON 02 DEC 2008
L13           0 L11
L14           0 L12

     FILE 'HCAPLUS' ENTERED AT 17:12:38 ON 02 DEC 2008
L15           3 L11
L16           2 L12

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:12:47 ON 02 DEC 2008
L17           4 L11
L18           3 L12

=>
```